Conversely, point estimates for tirzepatide showed a potential modest advantage for heart failure endpoints, with CIs compatible with no difference, consistent with recent data supporting protective effects of semaglutide and tirzepatide on heart failure outcomes and a potential incremental benefit with the latter 22
In that setting, particularly among those with underlying heart or kidney disease, the drugs helped improve blood sugar levels, lowered the risk of related complications, aided weight reduction, and reduced the likelihood of early death
Many patients continue losing weight after making small adjustments to their treatment plan under medical supervision
This innovation will increase the therapeutic potential of mAbs in CVD, where multiple signaling pathways need to be modulated
The complete metabolic and organ baseline before starting GLP-125 markers across blood sugar, insulin, lipids, liver and kidney function
VITAstir is a leading provider of injectable vitamins